Locana Revenue and Competitors

Location

$155.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Locana's estimated annual revenue is currently $5.7M per year.(i)
  • Locana's estimated revenue per employee is $77,500
  • Locana's total funding is $155.6M.

Employee Data

  • Locana has 73 Employees.(i)
  • Locana grew their employee count by -21% last year.

Locana's People

NameTitleEmail/Phone
1
Associate Director, Human ResourcesReveal Email/Phone
2
ChairmanReveal Email/Phone
3
Director (former CEO)Reveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Sr. Development Associate IIReveal Email/Phone
6
Sr. Research AssociateReveal Email/Phone
7
Senior Research Associate IReveal Email/Phone
8
Associate ScientistReveal Email/Phone
9
Executive Director, CMC Analytical and Formulation DevelopmentReveal Email/Phone
10
Director, Gene Therapy Process DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Locana?

We are creating a new class of precision medicines to treat a range of human genetic diseases. Locana's RNA-targeting technology platform allows us to precisely address these mutations on the level of RNA. By targeting RNA, our approach avoids the risk of off-target effects in DNA and is suited to address many diseases linked to dysfunctional processing of RNA. The wide range of potential indications is supported by the modularity of our RNA-targeting gene therapies which are composed of interchangeable components that provide exquisite control of specificity and activity. We are working hard to realize the potential of RNA-targeting gene therapy to treat a range of devastating illnesses. With world leadership in RNA biology and RNA-mediated disease and a top tier Board of Directors and panel of Scientific Advisors, we are poised to develop the next generation of genomic medicines for functional correction of disease.

keywords:N/A

$155.6M

Total Funding

73

Number of Employees

$5.7M

Revenue (est)

-21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Locana News

2022-04-17 - Locana Awarded Wildlife Habitat Analysis Task Order for The ...

Denver (April 27, 2022) — Locana, a leading geographic data and technology company, has won a 10-year National Geospatial Data and...

2022-03-22 - Locana and Bent Ear Solutions form strategic alliance

Locana was formerly known as Critigen. The companies will work closely with clients and identify issues, challenges and mission priorities to...

2021-01-03 - Locanabio Raises $100 Million in Series B Financing

Photo courtesy of Locanabio. Locanabio will pursue gene therapy treatments for severe neurodegenerative and neuromuscular diseases. San Diego-based Locanabio, a private preclinical-stage biotech company, has raised a $100 million Series B financing to support the advancement of its RNA-targetin ...

2020-12-14 - Locanabio Finds $100M For Gene Therapy

San Diego-based Locanabio, a biotech startup developing gene therapy to treat neurodegenerative, neuromuscular, and retinal diseases, has raised $100M in a Series B funding, the company said this morning. The funding was led by Vida Ventures, and also included RA Capital Management, Invus, Acuta ...

2020-12-14 - San Diego’s Locanabio raises $100 million for treatments aimed at degenerative diseases

Locanabio, a San Diego gene therapy company focused on treatments for severe neurodegenerative diseases such as Huntington’s and Lou Gehrig’s disease, has raised $100 million in a second round of venture capital funding. The Torrey Pines Mesa company will use the money for further pre-clinical ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.4M736%N/A
#2
$17.7M7355%N/A
#3
$19.1M734%N/A
#4
$17.7M733%N/A
#5
$17.7M7359%N/A